Related Experiment Videos

Replication-selective microbiological agents: fighting cancer with targeted germ warfare

¹Imperial Cancer Research Fund, Molecular Oncology Unit, Program for Viral and Genetic Therapy of Cancer, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 ONN, United Kingdom. d.kirn@icrf.icnet.uk

The Journal of Clinical Investigation

|April 5, 2000

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).

Oncoimmunology·2019

A Phase II Trial of Intratumoral Injection with a Selectively Replicating Adenovirus (ONYX-015) in Patients with Recurrent, Refractory Squamous Cell Carcinoma of the Head and Neck.

Methods in molecular medicine·2011

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

Gene therapy·2010

Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.

Cancer gene therapy·2009

Genetically based therapeutics for cancer: similarities and contrasts with traditional drug discovery and development.

Molecular therapy : the journal of the American Society of Gene Therapy·2005

Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts.

British journal of cancer·2003

See all related articles